

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection

- ▶ **Humalog Mix25** (Eli Lilly and Company Ltd)
Insulin lispro 25 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 100units/ml suspension for injection 10ml vials | 1 vial [PoM] £16.61 DT = £16.61
 Humalog Mix25 100units/ml suspension for injection 3ml cartridges | 5 cartridge [PoM] £29.46 DT = £29.46
- ▶ **Humalog Mix25 KwikPen** (Eli Lilly and Company Ltd)
Insulin lispro 25 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 KwikPen 100units/ml suspension for injection 3ml pre-filled pens | 5 pre-filled disposable injection [PoM] £30.98 DT = £30.98
- ▶ **Humalog Mix50** (Eli Lilly and Company Ltd)
Insulin lispro 50 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 50 unit per 1 ml Humalog Mix50 100units/ml suspension for injection 3ml cartridges | 5 cartridge [PoM] £29.46 DT = £29.46
- ▶ **Humalog Mix50 KwikPen** (Eli Lilly and Company Ltd)
Insulin lispro 50 unit per 1 ml, Insulin lispro (as Insulin lispro protamine) 50 unit per 1 ml Humalog Mix50 KwikPen 100units/ml suspension for injection 3ml pre-filled pens | 5 pre-filled disposable injection [PoM] £30.98 DT = £30.98

INSULINS > LONG-ACTING

Insulin degludec

08-Feb-2019

(Recombinant human insulin analogue—long acting)

● INDICATIONS AND DOSE

Diabetes mellitus

- ▶ BY SUBCUTANEOUS INJECTION
- ▶ Child 1-17 years: Dose to be given according to requirements
- ▶ Adult: Dose to be given according to requirements

- **INTERACTIONS** → Appendix 1: insulins
- **SIDE-EFFECTS**
 - ▶ Rare or very rare Urticaria
- **PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.
- **PRESCRIBING AND DISPENSING INFORMATION** Insulin degludec (*Tresiba*[®]) is available in strengths of 100 units/mL (allows 1-unit dose adjustment) and 200 units/mL (allows 2-unit dose adjustment)—ensure correct strength prescribed.
- **NATIONAL FUNDING/ACCESS DECISIONS**

All Wales Medicines Strategy Group (AWMSG) decisions
 AWMSG No. 3158

 - ▶ In adults The *All Wales Medicines Strategy Group* has advised (October 2016) that insulin degludec (*Tresiba*[®]) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adult patients where treatment with a basal insulin analogue is considered appropriate.
 AWMSG No. 3158
 - ▶ In children The *All Wales Medicines Strategy Group* has advised (October 2016) that insulin degludec (*Tresiba*[®]) is **not** recommended for use within NHS Wales for the treatment of diabetes mellitus in adolescents and children from the age of 1 year.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- ▶ **Tresiba FlexTouch** (Novo Nordisk Ltd)
Insulin degludec 100 unit per 1 ml Tresiba FlexTouch 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection [PoM] £46.60 DT = £46.60

Insulin degludec 200 unit per 1 ml Tresiba FlexTouch 200units/ml solution for injection 3ml pre-filled pens | 3 pre-filled disposable injection [PoM] £55.92 DT = £55.92

- ▶ **Tresiba Penfill** (Novo Nordisk Ltd)
Insulin degludec 100 unit per 1 ml Tresiba Penfill 100units/ml solution for injection 3ml cartridges | 5 cartridge [PoM] £46.60 DT = £46.60

Insulin degludec with liraglutide

27-Jul-2018

The properties listed below are those particular to the combination only. For the properties of the components please consider, insulin degludec above, liraglutide p. 737.

● INDICATIONS AND DOSE

As add-on to oral antidiabetics in type 2 diabetes mellitus not controlled by oral antidiabetics alone

- ▶ BY SUBCUTANEOUS INJECTION
- ▶ Adult: Initially 10 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

When transferring from basal insulin in type 2 diabetes mellitus not controlled by oral antidiabetics in combination with basal insulin

- ▶ BY SUBCUTANEOUS INJECTION
- ▶ Adult: Initially 16 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

- **INTERACTIONS** → Appendix 1: insulins · liraglutide
- **PATIENT AND CARER ADVICE** Counselling advised on administration. Show container to patient and confirm that patient is expecting the version dispensed.
- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) decisions
 The *Scottish Medicines Consortium* has advised (October 2015) that insulin degludec with liraglutide (*Xultophy*[®]) is accepted for restricted use within NHS Scotland for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or with basal insulin do not provide adequate glycaemic control.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- ▶ **Xultophy** (Novo Nordisk Ltd)
Liraglutide 3.6 mg per 1 ml, Insulin degludec 100 unit per 1 ml Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pens | 3 pre-filled disposable injection [PoM] £95.53 DT = £95.53

Insulin detemir

(Recombinant human insulin analogue—long acting)

● INDICATIONS AND DOSE

Diabetes mellitus

- ▶ BY SUBCUTANEOUS INJECTION
- ▶ Child 2-17 years: According to requirements
- ▶ Adult: According to requirements

- **INTERACTIONS** → Appendix 1: insulins
- **SIDE-EFFECTS**
 - ▶ Uncommon Refraction disorder
- **PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin p. 755 is recommended where longer-acting insulins are needed; insulin detemir may also be considered where longer-acting insulins are needed.